The efficacy of intravenous nimodipine in the treatment of focal cerebral ischemia in a primate model

M. N. Hadley, J. M. Zabramski, R. F. Spetzler, Daniele Rigamonti, M. S. Fifield, P. C. Johnson, B. Ljunggren, L. Brandt

Research output: Contribution to journalArticle

Abstract

The clinical and pathological effects of nimodipine on cerebral infarction were investigated in 12 male baboons. In randomized/blind trials, six animals given intravenous nimodipine (2 μg/kg/min load, 1 μg/kg/min maintenance) for 96 hours starting 50 minutes before 6-hour double-clip occlusion of the middle cerebral artery were compared to 6 control animals. Standardized neurological examinations were performed by examiners blinded to the animals' therapy on Day 7 and Day 14 after stroke. On Day 14 the animals were killed. The brains were studied pathologically, and the relative areas of infarction were quantified. Intracranial pressure was lower in nimodipine-treated animals; however, the range of intracranial pressure values in each group was broad. Two control animals with high intracranial pressure died. There were no deaths among the nimodipine-treated animals. The neurological scores on Days 7 (P ≤ 0.01) and 14 (P ≤ 0.05) were significantly different between the two groups. The nimodipine-treated animals had less clinical evidence of infarction compared to controls. Nimodipine-treated animals tended to have smaller areas of infarction; however, the difference between the two groups was not statistically significant. The infusion of nimodipine in the treatment of focal cerebral ischemia is safe and does not appear to aggravate the extent of infarction or to exacerbate intracranial hypertension. The clinical neurological evaluations indicate that nimodipine may improve or preserve neurological outcome after stroke.

Original languageEnglish (US)
Pages (from-to)63-70
Number of pages8
JournalNeurosurgery
Volume25
Issue number1
StatePublished - 1989
Externally publishedYes

Fingerprint

Nimodipine
Brain Ischemia
Primates
Infarction
Intracranial Pressure
Stroke
Intracranial Hypertension
Papio
Middle Cerebral Artery Infarction
Cerebral Infarction
Neurologic Examination
Surgical Instruments
Maintenance

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Hadley, M. N., Zabramski, J. M., Spetzler, R. F., Rigamonti, D., Fifield, M. S., Johnson, P. C., ... Brandt, L. (1989). The efficacy of intravenous nimodipine in the treatment of focal cerebral ischemia in a primate model. Neurosurgery, 25(1), 63-70.

The efficacy of intravenous nimodipine in the treatment of focal cerebral ischemia in a primate model. / Hadley, M. N.; Zabramski, J. M.; Spetzler, R. F.; Rigamonti, Daniele; Fifield, M. S.; Johnson, P. C.; Ljunggren, B.; Brandt, L.

In: Neurosurgery, Vol. 25, No. 1, 1989, p. 63-70.

Research output: Contribution to journalArticle

Hadley, MN, Zabramski, JM, Spetzler, RF, Rigamonti, D, Fifield, MS, Johnson, PC, Ljunggren, B & Brandt, L 1989, 'The efficacy of intravenous nimodipine in the treatment of focal cerebral ischemia in a primate model', Neurosurgery, vol. 25, no. 1, pp. 63-70.
Hadley MN, Zabramski JM, Spetzler RF, Rigamonti D, Fifield MS, Johnson PC et al. The efficacy of intravenous nimodipine in the treatment of focal cerebral ischemia in a primate model. Neurosurgery. 1989;25(1):63-70.
Hadley, M. N. ; Zabramski, J. M. ; Spetzler, R. F. ; Rigamonti, Daniele ; Fifield, M. S. ; Johnson, P. C. ; Ljunggren, B. ; Brandt, L. / The efficacy of intravenous nimodipine in the treatment of focal cerebral ischemia in a primate model. In: Neurosurgery. 1989 ; Vol. 25, No. 1. pp. 63-70.
@article{a10ccc70abc64b22a854759c352fb865,
title = "The efficacy of intravenous nimodipine in the treatment of focal cerebral ischemia in a primate model",
abstract = "The clinical and pathological effects of nimodipine on cerebral infarction were investigated in 12 male baboons. In randomized/blind trials, six animals given intravenous nimodipine (2 μg/kg/min load, 1 μg/kg/min maintenance) for 96 hours starting 50 minutes before 6-hour double-clip occlusion of the middle cerebral artery were compared to 6 control animals. Standardized neurological examinations were performed by examiners blinded to the animals' therapy on Day 7 and Day 14 after stroke. On Day 14 the animals were killed. The brains were studied pathologically, and the relative areas of infarction were quantified. Intracranial pressure was lower in nimodipine-treated animals; however, the range of intracranial pressure values in each group was broad. Two control animals with high intracranial pressure died. There were no deaths among the nimodipine-treated animals. The neurological scores on Days 7 (P ≤ 0.01) and 14 (P ≤ 0.05) were significantly different between the two groups. The nimodipine-treated animals had less clinical evidence of infarction compared to controls. Nimodipine-treated animals tended to have smaller areas of infarction; however, the difference between the two groups was not statistically significant. The infusion of nimodipine in the treatment of focal cerebral ischemia is safe and does not appear to aggravate the extent of infarction or to exacerbate intracranial hypertension. The clinical neurological evaluations indicate that nimodipine may improve or preserve neurological outcome after stroke.",
author = "Hadley, {M. N.} and Zabramski, {J. M.} and Spetzler, {R. F.} and Daniele Rigamonti and Fifield, {M. S.} and Johnson, {P. C.} and B. Ljunggren and L. Brandt",
year = "1989",
language = "English (US)",
volume = "25",
pages = "63--70",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The efficacy of intravenous nimodipine in the treatment of focal cerebral ischemia in a primate model

AU - Hadley, M. N.

AU - Zabramski, J. M.

AU - Spetzler, R. F.

AU - Rigamonti, Daniele

AU - Fifield, M. S.

AU - Johnson, P. C.

AU - Ljunggren, B.

AU - Brandt, L.

PY - 1989

Y1 - 1989

N2 - The clinical and pathological effects of nimodipine on cerebral infarction were investigated in 12 male baboons. In randomized/blind trials, six animals given intravenous nimodipine (2 μg/kg/min load, 1 μg/kg/min maintenance) for 96 hours starting 50 minutes before 6-hour double-clip occlusion of the middle cerebral artery were compared to 6 control animals. Standardized neurological examinations were performed by examiners blinded to the animals' therapy on Day 7 and Day 14 after stroke. On Day 14 the animals were killed. The brains were studied pathologically, and the relative areas of infarction were quantified. Intracranial pressure was lower in nimodipine-treated animals; however, the range of intracranial pressure values in each group was broad. Two control animals with high intracranial pressure died. There were no deaths among the nimodipine-treated animals. The neurological scores on Days 7 (P ≤ 0.01) and 14 (P ≤ 0.05) were significantly different between the two groups. The nimodipine-treated animals had less clinical evidence of infarction compared to controls. Nimodipine-treated animals tended to have smaller areas of infarction; however, the difference between the two groups was not statistically significant. The infusion of nimodipine in the treatment of focal cerebral ischemia is safe and does not appear to aggravate the extent of infarction or to exacerbate intracranial hypertension. The clinical neurological evaluations indicate that nimodipine may improve or preserve neurological outcome after stroke.

AB - The clinical and pathological effects of nimodipine on cerebral infarction were investigated in 12 male baboons. In randomized/blind trials, six animals given intravenous nimodipine (2 μg/kg/min load, 1 μg/kg/min maintenance) for 96 hours starting 50 minutes before 6-hour double-clip occlusion of the middle cerebral artery were compared to 6 control animals. Standardized neurological examinations were performed by examiners blinded to the animals' therapy on Day 7 and Day 14 after stroke. On Day 14 the animals were killed. The brains were studied pathologically, and the relative areas of infarction were quantified. Intracranial pressure was lower in nimodipine-treated animals; however, the range of intracranial pressure values in each group was broad. Two control animals with high intracranial pressure died. There were no deaths among the nimodipine-treated animals. The neurological scores on Days 7 (P ≤ 0.01) and 14 (P ≤ 0.05) were significantly different between the two groups. The nimodipine-treated animals had less clinical evidence of infarction compared to controls. Nimodipine-treated animals tended to have smaller areas of infarction; however, the difference between the two groups was not statistically significant. The infusion of nimodipine in the treatment of focal cerebral ischemia is safe and does not appear to aggravate the extent of infarction or to exacerbate intracranial hypertension. The clinical neurological evaluations indicate that nimodipine may improve or preserve neurological outcome after stroke.

UR - http://www.scopus.com/inward/record.url?scp=0024341458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024341458&partnerID=8YFLogxK

M3 - Article

C2 - 2755582

AN - SCOPUS:0024341458

VL - 25

SP - 63

EP - 70

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 1

ER -